One sentence summary: Cells from uninfected sheep exposed to the agent responsible for paratuberculosis had a greater capacity to kill the intracellular infectious agent compared to vaccinated animals that were infected, indicating that this in vitro assay has the potential to gauge actual protectiveness of a vaccine. Editor: Patrick Brennan † Hannah B. Pooley, http://orcid.org/0000-0003-2238-3906
INTRODUCTION
Johne's disease (JD) or paratuberculosis is a chronic intestinal enteritis of ruminants resulting in wasting and eventual death. The disease is caused by Mycobacterium avium subspecies paratuberculosis (MAP), a fastidious slow growing bacterium, and is a significant financial burden to producers. Economic losses associated with JD are substantial; for example, in the USA the estimated net economic impact to the dairy industry is US$200-$1500 million annually (Garcia and Shalloo 2015) . In Australia, average losses in excess of AU$13 000 per year are seen on infected sheep properties (Bush, Windsor and Toribio 2006) . Currently there is no treatment for JD, so emphasis has been placed on preventative control measures such as biosecurity to reduce spread to susceptible properties and vaccination to reduce the incidence of clinical disease on affected farms (Keys 2010) . The control of ovine JD has been facilitated in Australia by vaccination, which has reduced mortalities on heavily infected farms by up to 90% (Reddacliff et al. 2006) . The three commercially available vaccines are all formulated using an inactivated whole-cell preparation of MAP or M. avium subsp. avium (MAA) combined with an adjuvant (Bannantine et al. 2014) . However, the inability of these vaccines to prevent infection and faecal shedding of MAP necessitates the development of more efficacious vaccines to reduce the financial burden of this disease.
The success of pathogenic mycobacterial species such as MAP is partly due to their ability to evade the host's extracellular immune response and reside in an intracellular location. Mycobacterial infections are chronic in nature, difficult to diagnose at the early stages of infection and sterile eradication is almost impossible. The infection status of the host depends on the balance between pathogen survival within macrophages and the host's cell-mediated immune response (Kaufmann 1993) .
Not surprisingly, due to the slow progression of disease and the cost of trials in ruminants, vaccine screening for JD using either in vitro systems or non-ruminant small animal models is popular (Worku and Hoft 2000; de Pascalis et al. 2012; Fletcher et al. 2013; Bannantine et al. 2014; Lamont et al. 2014; Tanner et al. 2016) . In vitro assays can be used to examine the ability of macrophages or peripheral blood mononuclear cells (PBMCs) to kill or inhibit the growth of intracellular mycobacteria (Carpenter, Fray and Gormley 1997; Denis, Wedlock and Buddle 2004 ). Surviving intracellular bacteria are then released via lysis of the macrophage and enumerated. Cellmediated immune responses are central to effective control of mycobacterial infections, and as such are an important target for vaccines. Interactions between T cells (CD4 + and CD8 + T cells and gamma delta (γ δ) T cells) and a strong interferon gamma (IFNγ ) response influence disease progression Davis 1992, 1993; de Silva et al. 2013 de Silva et al. , 2015 . In vitro, the presence of antigen-specific effector T cells is required to limit intracellular growth of mycobacteria (Worku and Hoft 2000) . An effective vaccine should induce antigen-specific effector memory (T EM ) and central memory (T CM ) lymphocytes, which can rapidly facilitate killing of intracellular bacteria upon exposure of the host to the specific pathogen (Seder and Hill 2000) . Vaccination of cattle with Bacillus-Calmette-Guerin (BCG) inhibits in vitro replication of virulent M. bovis by lymphocytes, in particular CD4 + T cells but the relationship between this function and disease outcome has not been assessed (Carpenter, Fray and Gormley 1997; Denis, Wedlock and Buddle 2004) . We aimed to develop a system that combines both in vivo and in vitro aspects. The Integrated Vaccine Screening system commences with the vaccination of sheep, which allows an immune response to develop in the presence of the animal's entire immune repertoire. An in vitro component follows, based on a mycobacterial growth inhibition assay (MGIA) that has been specifically optimised for MAP. In our in vitro assay, monocytes from vaccinated sheep are cultured with MAP prior to the addition of autologous lymphocytes. At the end of the culture period, viable intracellular MAP are quantified using a rapid viability enumeration method we have recently developed (Pooley et al. 2016) . This method uses MAP standards to enable calculation of the concentration of viable bacteria based on their growth rate. In this preliminary study, we have assessed this Integrated Vaccine Screening system using a commercial vaccine that protects against disease and has related disease outcome to the functional performance of the animal's cells in the in vitro assay.
This integrated methodology has the potential to enable practical assessment of novel vaccines under conditions relevant to target species, using more economically feasible methods, potentially also reducing the number of animals required for experimentation.
MATERIALS AND METHODS

Animals
The experimental trial was approved by the University of Sydney Animal Ethics Committee (ref no 6064). Vaccination with Gudair R was performed in accordance with the manufacturer's instructions and at 6 weeks post-vaccination a cohort was moved to quarantine paddocks and inoculated with MAP (Telford 9.2). The inoculation consisted of three oral doses (within a 4-week period) as described by Begg et al. (2010) and a total of 9.25 × 10 8 viable MAP organisms. A non-vaccinated cohort was similarly exposed to MAP at the same time. Unexposed animals, vaccinated and non-vaccinated, were kept in separate paddocks to their exposed counterparts. A total of 45 animals from four different groups were used for this study: non-vaccinated without MAP exposure (n = 5) (non-vaccinated controls), non-vaccinated with MAP exposure (n = 16), Gudair vaccinated without MAP exposure (n = 5) (vaccinated controls) and Gudair vaccinated with MAP exposure (n = 19). All MAP exposed animals were retrospectively categorised based on culture of MAP from gut tissues at necropsy (12 months post-exposure). Animals with positive tissue cultures were classified as infected and those with negative results were classified as uninfected.
Mycobacteria preparation
Suspensions of MAP (sheep strain (S) Telford 9.2, IS900 RFLP S1 type, IS1311 S pattern) stored at -80
• C were used for all experiments. Suspensions were thawed at room temperature and washed by pelleting the cells in a microfuge (Beckman Coulter, Microfuge R ) at 5000 × g for 5 min. The supernatant was aspirated and the cell pellet was resuspended in 1 mL of 0.1 M phosphate buffered saline (PBS); this process was repeated twice. After the second centrifugation, cells were resuspended at a concentration of 1.08 × 10 10 /mL in M7H9C medium (mycobacterial culture medium) (7). To ensure a single-cell suspension, the suspension was passed through a 26-gauge needle three times, and MAP was incubated for 24 h at 37
• C in an atmosphere of 5% CO 2 prior to use.
Optimisation
Infection using murine macrophages Tissue culture-treated chamber slides (Thermo Scientific) were seeded with 2 × 10 5 murine macrophages (RAW 264.7, European
Collection of Cell Culture, Wiltshire, UK) in 300 μL of cell culture media (RPMI 1640 with 25mM HEPES, 10% foetal calf serum and 0.22% β-mercaptoethanol, 1% penicillin streptomycin and 30% glutamine) per chamber and incubated overnight at 37
• C in an atmosphere of 5% CO 2 . Cell culture media was aspirated from each slide chamber and cells were exposed to infection medium (live MAP:macrophages at MOI of 0.1:1, 1:1 or 10:1 in 300 μL of cell culture media without penicillin and streptomycin) from 1 to 24 h. Each slide had one negative control chamber, with uninfected macrophages. Following culture, the culture medium was removed, slides were air-dried and heat-fixed (1 h at 80
prior to staining with Ziehl-Neelsen.
MOI and incubation duration
The effect of MOI and incubation duration on uptake of MAP by ovine monocytes and monocyte killing ability was assessed (Table 1) . At the completion of each treatment, the supernatant was removed from wells and monocytes were then lysed. The lysate was inoculated into mycobacterial culture medium and viable MAP quantified by a rapid culture and qPCR method previously described by Pooley et al. (2016) . qPCR was performed using primers designed for the MAP-specific gene ISMAP02 ( 
Ovine MGIA
Ovine blood collected at 13 months post-vaccination (11.5 months post MAP-exposure) from the jugular vein was used to isolate PBMCs. Vacutainers were centrifuged at 1455 × g for 20 min followed by removal of the buffy coat layer, which was mixed with 3 mL of sterile PBS. The buffy coat solution was added to a Leucosep tube (Greiner Bio-One #163290) with 3 mL of Ficoll-Paque PLUS (GE Healthcare) and centrifuged at 754 × g for 30 min. The interface containing PBMCs was aspirated and residual red blood cells lysed using ammonium chloride (AMCO) lysis (0.83% NH 4 Cl, 0.1% KHCO 3 , 0.01M EDTA pH 7.5) before dilution 1:1 with sterile PBS and centrifugation at 233 × g for 10 min. The cells were washed three times with PBS before being resuspended in cell culture media (without penicillin streptomycin). The basic steps for the MGIA following PBMC isolation are shown in Fig. 1 . PBMC resuspended in cell culture medium were seeded at 4 × 10 5 cells/well (6 wells/animal) and incubated at 37
CO 2 (culture conditions were similar for subsequent steps) for 3 h to allow adherence. The non-adherent (lymphocytes) and adherent (monocytes) PBMC fractions were then counted and viability assessed on a flow cytometer (Guava easyCyte HT Sampling Flow Cytometer (Merck Millipore)). Data were analysed using ViaCount in Guavasoft 2.7 software, and only samples with viability above 80% were retained for use in the system. The PBMC fractions (monocytes, lymphocytes) from each well were cultured separately. Lymphocytes were maintained in cell culture media without stimulation until they were required. MAP was added to four replicate monocyte wells (MOI 0.1:1) and two were left MAP-free as negative controls. The plates were incubated overnight. Supernatants from monocyte wells were gently aspirated and replaced with either fresh culture medium (two wells with monocytes alone and two wells with MAP + monocytes) or autologous lymphocytes (two wells with MAP + monocytes) and incubated for a further 24 h. At the end of the culture period, adherent cells were lysed and viable intracellular bacteria enumerated using the rapid culture and qPCR method (Pooley et al. 2016 ) and ISMAP02 primers, as described above (optimisation of MOI and incubation duration).
Data analysis
Statistical analysis was performed using Genstat (16th edition; VSN International Ltd, Hemel Hemstead, UK) and Excel (Microsoft 2016) . A linear mixed model was used to assess the interaction of macrophage incubation period prior to infection, MOI, infection duration as well as sample location (lysate or supernatant) on killing ability of macrophages during assay optimisation. In this model, treatment group was included as a random effect. A linear mixed model was used in the ovine MGIA to determine the effect of vaccination, exposure and infection status of the animal on PBMC in vitro killing ability. Animal was fitted as a random effect to account for multiple replicates within the MGIA. In each linear mixed model, the test assumptions were checked by secondary diagnostics and found to be valid. Post tests for the significance of differences between predicted means were calculated in Excel using Student's t-test applying the standard error of the difference for each pair of predicted means. Significance was assessed at the 5% level.
Analysis of the difference in killing ability of monocytes alone and monocytes co-cultured with autologous lymphocytes was performed using a paired t-test.
RESULTS
Optimisation of infection using murine macrophages
A ratio of 1 bacteria to 10 macrophages (MOI 0.1:1) and 24 h culture incubation were selected as the optimal conditions for the in vitro infection protocol. Under these conditions, there were one to two bacteria per infected cell ( Fig. 2A) . At higher MOI, there were conversely fewer infected macrophages and the intracellular bacteria were clumped, despite taking measures to ensure single-cell suspension prior to incubation with the macrophages (Fig. 2B-D) . In addition, at these higher MOIs, the number of infected cells did not increase over time at early time points compared to the lower MOI (data not shown).
Optimisation of MOI and incubation duration
The effects of MOI and incubation duration on ovine monocyte infection were also examined. Live bacteria within macrophages and live bacteria remaining in the supernatant were quantified using a previously developed rapid viability assay (Pooley et al. 2016) . The effects of macrophage incubation prior to infection, MOI and infection duration were examined for both macrophage lysates and supernatant samples using a linear mixed model. As no significant interactions were found, the interaction terms for macrophage incubation period, MOI and infection duration were Ovine monocytes, either on the day of isolation or after a 24 h culture period, were incubated at an MOI of 1:1 or 0.1:1 (MAP: monocyte) for 24-48 h. Concentrations of live MAP in monocyte lysates (L) and culture supernatants (S) at the end of the monocyte culture period were quantified, n = 2 per treatment. L1 and S1: monocytes infected on day of isolation at an MOI of 1:1 for 24 h; L2 and S2: monocytes cultured for 24 h prior to infection at an MOI of 0.1:1, incubated for a further 24 h; L3 and S3: monocytes cultured for 24 h prior to infection at an MOI of 1:1, incubated for a further 24 h; L4 and S4: monocytes infected on day of isolation at an MOI of 0.1:1 for 48 h. Groups with different letters are significantly different (P < 0.05).
removed from the final model. The location of the sample, either macrophage lysate or supernatant, was the only effect found to be significant (P < 0.05). The supernatants from macrophage cultures had significantly higher concentrations of viable MAP compared to monocyte lysates (P < 0.05) (Fig. 3) .
Ovine MGIA
The effects of vaccination, exposure and infection status on the ability of ovine PBMCs to control in vitro MAP infection were assessed using the optimised MGIA assay (Fig. 4) . A linear mixed model was fitted with vaccination, exposure and infection status as fixed effects and animal as the random effect to account for repeated measures. No significant interactions were found so interaction terms were removed from the final model for statistical analysis. In the final model, there were significant main effects of vaccination (P < 0.05) and infection status (P < 0.01) (Fig. 4) . When results for the non-vaccinated and vaccinated groups were analysed, post tests showed that there was no significant difference in cellular MAP killing ability between vaccinated exposed animals which were infected or uninfected and their non-vaccinated exposed counterparts with the same infection status. Furthermore, there were also no significant differences seen when the vaccinated and non-vaccinated controls were compared. However, all MAP exposed animals had a higher intracellular MAP killing ability compared to their respective controls (P < 0.05). There was a significantly higher killing ability in cells from non-vaccinated exposed uninfected sheep compared to vaccinated exposed infected (P = 0.029) (Fig. 4) . There was no significant difference in the MAP killing ability of monocytes in the presence or absence of autologous lymphocytes; all the different treatment groups were combined for this analysis (n = 16 sheep, paired t-test P > 0.05).
The Integrated Vaccine Screening system detected as few as 0.006 intracellular MAP/ml, and had an average difference of 0.14 MAP/ml between replicates within the assay.
DISCUSSION
The aim of this work was to assess if the ability of PBMCs to kill intracellular MAP could be used to gauge vaccine protection against paratuberculosis in sheep. The incentive for undertaking this study was to reduce the cost and length of time required to screen novel vaccines in a ruminant model, which is often an obstacle to effective vaccine development (Worku and Hoft 2000; Fletcher et al. 2013; Bannantine et al. 2014; Lamont et al. 2014; Tanner et al. 2016) . We hypothesised that, since vaccination should activate the adaptive immune response and produce cells capable of responding rapidly during subsequent encounters with the pathogen, this memory response should be readily detected under suitable conditions in vitro. To do this, we first developed a rapid in vitro assay to assess the ability of PBMC to kill MAP, next we used a validated experimental mycobacterial infection model in sheep together with a commercial vaccine (Gudair) to assess this assay.
The capacity to assess cellular function has the potential to reflect an animal's overall ability to overcome disease. Using this Integrated Vaccine Screening system, we found that exposure significantly enhanced the ability of PBMC to kill MAP, in both unvaccinated and vaccinated animals. This is supported by the finding that PBMCs from non-vaccinated MAP exposed but uninfected animals (those with the optimal natural protective immunological response) were significantly better at limiting the number of intracellular MAP compared to vaccinated infected sheep (those with an inferior immunological response despite vaccination). This is an important finding as these two groups represent extreme outcomes in protection against MAP infection. The ability to detect a significant difference between these groups strongly suggests that the system we have developed, and assessment of the killing ability of PBMCs specifically, is a promising surrogate for vaccine efficacy trials.
Surprisingly, we did not observe an enhanced MAP killing ability in the vaccinated controls compared to the nonvaccinated controls. T cells in the latter group should still be in a naïve state as they have not had any previous exposure to MAP antigens. However, the vaccinated control sheep are expected to have a pool of memory T cells primed by Gudair vaccination (Sallusto, Geginat and Lanzavecchia 2004) . These animals were assessed more than 1 year post-vaccination by which time the memory response may have waned. A better understanding of memory T cell subsets generated after Gudair vaccination would be beneficial in fully understanding this effect.
These results can be affected by factors relating to not only the MGIA (in vitro) but also the state of the animal's immune response (in vivo). The timing of immune response assessment, the duration of co-culture of infected monocytes and lymphocytes and the type of memory response generated by vaccination may be contributing factors, which are important to consider in this type of vaccine screening method. Gudair vaccination is highly effective at preventing clinical disease, especially in heavily infected flocks of sheep. However, Gudair fails to prevent infection in all animals, and some still succumb to clinical disease (Reddacliff et al. 2006) . Therefore, it remains imperative that we aim to understand the mechanism(s) of action of this specific vaccine and also what constitutes a protective response against paratuberculosis in order to develop better vaccines.
We propose that each group of sheep in our experiment is likely to have different immune memory phenotypes that have shaped their responses in the in vitro assay (Fig. 5) . The development of T-cell memory progresses through stages of differentiation and enhanced effector function, which is driven by several factors including the strength and duration of stimulus received (Mackay et al. 1996; Lanzavecchia and Sallusto 2000; Reinhardt et al. 2001; Gett et al. 2003; MacLeod, Kappler and Marrack 2010) . Exposure to antigens from either live bacteria or vaccination leads to the priming/activation of naïve T cells and the development of a pool of memory T cells, mainly T CM and T EM . T CM have low effector function but high proliferative capacity, whereas T EM have a stronger effector function but lack proliferative capacity (Sallusto, Geginat and Lanzavecchia 2004; Farber, Yudanin and Restifo 2014; Macallan, Borghans and Asquith 2017) . When an animal re-encounters a pathogen, T EM mount a rapid and potent response and T CM proliferate to produce more effector cells and help to prolong the immune response (Sallusto et al. 1999; Iezzi, Scheidegger and Lanzavecchia 2001) .
The similar killing capacity in vaccinated and nonvaccinated exposed sheep was also surprising. The constant exposure of the non-vaccinated MAP exposed sheep (via faecal shedding of MAP from others in the flock) could have led to the development of immune responses whereby at 12 months post exposure they have a similar cellular killing capacity as the vaccinates. Further longitudinal assessment of the T-cell memory phenotype and killing ability of PBMCs is required from soon after vaccination or exposure.
Infection status of the vaccinated sheep did not significantly affect the killing ability of PBMC. The tissue tropism of different subsets of memory T cells could explain the difficulty in distinguishing between infected and uninfected animals based on PBMC killing ability. Tissue resident memory cells (T RM ) are a newly identified subset of memory T cells that, as their name suggests, reside in and have a specific tropism for tissue sites (McNeilly, McClure and Huntley 2008; Farber, Yudanin and Restifo 2014; Macallan, Borghans and Asquith 2017) . It is possible that if differences in killing ability exist in this subset of memory cells it would not be identified by our assay due to their scarcity in the circulation. The importance of T RM in protection against M. tuberculosis infection has recently been shown and the route of vaccination affected the production of these specific cell types (Perdomo et al. 2016) . Examination of the presence or absence of T RM in gut lesions of infected and uninfected sheep would provide evidence of their importance in paratuberculosis and could possibly be correlated with peripheral killing ability.
The results of our integrated vaccine screening system may also be impacted by conditions within the in vitro assay. After macrophage infection, lymphocytes and macrophages were co-cultured for 24 h. A longer co-culture period may be required for the lymphocytes to be fully effective. IFNγ production, which enhances intracellular killing of mycobacteria, does not occur until 24 h after exposure of lymphocytes to MAP-infected macrophages (Stabel 1996) .
Through this work we have met our two objectives: first, we have successfully developed a rapid system that can quantify the ability of PBMCs to kill MAP. The Integrated Vaccine Screening system is also sensitive and robust. Second, we have shown the validity of this system in an assessment of the effects of vaccination, exposure and infection status on the ability of sheep PBMCs to kill MAP. As we hypothesised, the ability of PBMCs from sheep to kill MAP in an in vitro assay is strongly influenced by the immune mechanisms at play after vaccination and exposure of the host. The success in identifying killing ability as a predictor of vaccine nonresponse suggests that this system can be utilised to assess novel vaccines and reduce the costs and time required for preliminary vaccine screening trials in the relevant natural host for paratuberculosis.
